Xilio Therapeutics (XLO)

• Market cap: $38.8M
• 1 day: -2.39%
• 5 days: -1.79%
• 1 month: -12.99%
• 3 months: 4.94%
• 6 months: 5.63%
• Year to date: -30.89%
• 1 year: -28.89%
• 5 years: -95.38%
• 10 years: -95.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Employees: 73